Piperidinylpyrazolopyrimidinones and their use

US10118930B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Manuel Ellermann · Wuppertal, DE
• Gaelle VALOT · Wuppertal, DE
• Yolanda Cancho Grande · Leverkusen, DE
• Jorma HAßFELD · Mülheim an der Ruhr, DE
• Tom KINZEL · Mülheim an der Ruhr, DE
• Johannes Köbberling · Neuss, DE
• Kristin Beyer · Mainz, DE
• Susanne Röhrig · Hilden, DE
• Michael Sperzel · Kierspe, DE
• Jan STAMPFUß · Mülheim an der Ruhr, DE
• Imke Meyer · Haan, DE
• Maria Köllnberger · Velbert, DE
• Nils Burkhardt · Velbert, DE
• Karl-Heinz Schlemmer · Wuppertal, DE
• Christian Stegmann · Berlin, DE
• Joachim Schuhmacher · Wuppertal, DE
• Matthias Werner · Wuppertal, DE
• Jörg Heiermann · Wesel, DE
• Willem Jan Hengeveld · Arnhem, NL

Key dates

• Filing date: Oct 30, 2015
• Grant date: Nov 6, 2018
• Expiry date: Oct 30, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.